BioLineRx (BLRX) SEC Filings & 10K Form

$0.66
-0.01 (-1.49%)
(As of 05/2/2024 ET)

Recent BioLineRx SEC Filings

DateFilerForm TypeView
04/17/2024
6:12 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
6:24 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2024
9:30 AM
BioLineRx (Filer)
Form 424B5
04/01/2024
9:35 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2024
3:57 PM
BioLineRx (Filer)
Form 20-F/A
03/26/2024
7:01 AM
BioLineRx (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/26/2024
6:06 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/04/2024
6:47 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/28/2024
6:08 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/16/2024
6:07 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/07/2024
11:15 PM
BioLineRx (Filer)
Form EFFECT
12/29/2023
3:15 PM
BioLineRx (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
12/29/2023
3:20 PM
BioLineRx (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/21/2023
6:05 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/12/2023
6:07 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2023
6:03 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
1:18 PM
BioLineRx (Subject)
Hong Seng Technology Ltd (Filed by)
Form SC 13D
10/12/2023
6:14 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/28/2023
6:11 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2023
6:07 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2023
6:15 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2023
5:45 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/08/2023
4:25 PM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2023
6:10 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/23/2023
3:16 PM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2023
6:06 AM
BioLineRx (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:BLRX) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners